KOL Insight: Hepatocellular Carcinoma [2020]

Maximum Purchase:
1 unit
Publication Date:
July 2020
Licence Type:
Multi-user licence
Adding to cart… The item has been added

Therapy Trends KOL Insight: Hepatocellular Carcinoma

KOLs anticipate Tecentriq and Avastin combination will become the standard of care for Hepatocellular Carcinoma (HCC) though COVID-19 may hinder the speed of its introduction. What role do KOLs see for current market leader Bayer's Nexavar and will the company's Stirvaga also come under pressure in the second-line setting? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Why are KOLs not positive about the prospects for AVEO Oncology and AstraZeneca's Fotivda/Imfinzi combination?
  • What safety issues do KOLs identify that may limit the potential of checkpoint inhibitors and their combinations such as Keytruda, Opdivo and Yervoy/Opdivo?
  • In what settings and combination do KOLs see value for Exelixis/Ipsen's Cabometyx?
  • Do KOLs see a future for Cure and Sure Biotech's tumour-derived heat shock protein Gp96 vaccine in HCC?

Examples of Therapies Covered

Nexavar Lenvima
Stivarga Cabometyx
Fotivda Cyramza
Keytruda Pexa-Vec
HSP gp96 Imfinzi
Pegargiminase Tislelizumab

Partial List of Participating KOLs

  • Raymond T Chung, MD, Director of Hepatology and Liver Center, Massachusetts General Hospital and Associate Professor of Medicine, Harvard Medical School, Boston, MA.
  • Robert J Lewandowski, MD, Professor of Radiology, Medicine and Surgery, Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL.
  • Josep M. Llovet, MD, Founder and Director of the Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School of Medicine, New York, NY; Professor of Research-ICREA in the BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Massimo Colombo, MD, Director of the Center for Translational Research in Liver Disease at Humanitas Research Hospital, Rozzano, Italy.
  • Tim Meyer, MBBS, PhD, FRCP, Consultant in Medical Oncology and Professor in Experimental Cancer Medicine, UCL, London, UK.
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Job Title*
Company Name *
Country Name *
Job Function
Account Owner